Login / Signup

Anticoagulation with edoxaban in patients with long Atrial High-Rate Episodes ≥24 hours.

Nina BecherTobias ToennisEmanuele BertagliaCarina Blomström-LundqvistAxel BrandesNuno CabanelasMelanie CalvertA John CammGregory ChlouverakisGheorghe-Andrei DanWolfgang DichtlHans Christoph DienerAlexander FierenzAndreas GoetteJoris R de GrootAstrid N L HermansGregory Y H LipAndrzej LubinskiEloi MarijonBéla MerkelyLluis MontAnn-Kathrin OzgaKim RajappanAndrea SarkozyDaniel ScherrRenate B SchnabelUlrich SchottenSusanne SehnerEmmanuel SimantirakisPanos VardasVasil VelchevDan WichterleAntonia ZapfPaulus F Kirchhof
Published in: European heart journal (2023)
This hypothesis-generating analysis does not find an interaction between AHRE duration and anticoagulation therapy in patients with device-detected AHRE and stroke risk factors. Further research is needed to identify patients with long AHRE at high stroke risk.
Keyphrases
  • atrial fibrillation
  • risk factors
  • left atrial
  • catheter ablation
  • venous thromboembolism
  • heart failure
  • stem cells
  • subarachnoid hemorrhage
  • brain injury
  • blood brain barrier